Form 4: Apellis Pharmaceuticals Acquired by Biogen

Apellis Pharmaceuticals has been acquired by Biogen in a transaction valued at $41.00 per share plus a contingent value right.

Summary

• Apellis Pharmaceuticals, Inc. has completed its merger with a subsidiary of Biogen Inc.
• Shareholders receive $41.00 per share in cash plus one non-transferable contingent value right (CVR) per share.
• The CVR entitles holders to potential additional payments of up to $4.00 per share upon the achievement of specific milestones.
• All outstanding stock options and restricted stock units (RSUs) were converted into cash and/or CVRs based on the merger terms.
• Apellis is now a wholly owned subsidiary of Biogen.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive outcome for shareholders, as the acquisition provides immediate liquidity at a premium and potential future upside via CVRs.

Positives

• Shareholders receive a guaranteed cash payment of $41.00 per share.
• Potential for additional upside of up to $4.00 per share through contingent value rights.
• Performance-based RSUs were settled at 200% of target based on relative total shareholder return performance.

Negatives

• Options with an exercise price of $45.00 or greater were cancelled without any consideration.
• The company ceases to exist as an independent publicly traded entity.

Risks

• The $4.00 per share CVR is contingent upon the achievement of specific, undisclosed milestones.
• CVRs are non-transferable, limiting liquidity for holders.
• Payments under the CVR are subject to tax withholding and potential reduction.

Future Outlook

The company has been acquired and is now a wholly owned subsidiary of Biogen; future operations will be integrated into the parent company.

Management Comments

• The compensation committee certified that the Relative TSR as of May 8, 2026 was at the 93.3rd percentile, resulting in a 200% payout for applicable RSUs.

Industry Context

StockSavvy.ai notes that this acquisition represents a significant consolidation in the biotechnology sector, with Biogen expanding its portfolio through the purchase of Apellis, a move consistent with large-cap pharma's strategy to acquire specialized clinical-stage or commercial-stage assets.

Comparison to Industry Standards

• The use of CVRs is a standard mechanism in biotech M&A to bridge valuation gaps between buyers and sellers regarding clinical trial outcomes.
• The $41.00 cash offer reflects a premium typical for mid-cap biotech acquisitions.

Stakeholder Impact

• Shareholders receive cash and CVRs.
• Employees and management are subject to the integration policies of the parent company, Biogen.

Next Steps

• Integration of Apellis into Biogen operations.
• Monitoring of milestones for potential CVR payouts.

Key Dates

Keywords

Apellis Pharmaceuticals, Biogen, Merger, Acquisition, APLS, Contingent Value Right, CVR